Cytokine Release Syndrome
Cytokine Release Syndrome - Related Videos
12:58
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
0 Views •
Cited by 2 •
2017
Described here is a method for producing exogenous cytokine in patient-derived xenograft (PDX) mice via weekly intraperitoneal injection of a cytokine-transduced stromal cell line. This method broadens the utility of PDX and provides the option for transient or sustained exogenous cytokine delivery in a multitude of PDX models.
06:37
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
0 Views •
2023
The use of cytokine release assay reference reagents allows for more reproducible and standardized in vitro safety profiles of immunotherapeutic monoclonal antibodies. Here we describe how cytokine release assays can be used alongside a reference reagent panel to predict the safety of some therapeutic monoclonal antibodies.
02:57
Assessing Antiviral Cytokine Production in Response to Viral Infection
0 Views •
2026
Source: Zhang, J., et al. Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production. J. Vis. Exp. (2014)This video demonstrates the process of infecting murine fibroblast cells with herpesvirus and monitoring the resulting antiviral cytokine release and gene expression. It outlines key steps, including viral infection, media collection for cytokine quantification, and cell harvesting for gene expression analysis.
05:18
Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
0 Views •
2023
The deep branch of the radial nerve can easily be compressed at the arcade of Frohse due to its anatomical features. Ultrasound-guided needle release combined with corticosteroid injection is an effective and safe treatment for deep branch radial nerve adhesion.
08:31
Conscious and Non-conscious Representations of Emotional Faces in Asperger's Syndrome
0 Views •
Cited by 5 •
2016
An EEG experimental protocol is designed to clarify the interplay between conscious and non-conscious representations of emotional faces in patients with Asperger's syndrome. The technique suggests that patients with Asperger's syndrome have deficits in non-conscious representation of emotional faces, but have comparable performance in conscious representation with healthy controls.
FAQs
Interleukin-6 can amplify the inflammatory response after immune-cell activation by participating in interactions among activated immune cells, endothelial cells, and myeloid cells. This interconnected signaling helps explain why an initially localized treatment response may develop into systemic effects. Studying these pathways helps cancer researchers identify mechanisms that could be monitored or modulated during immunotherapy.
Endothelial and myeloid cells are important because cytokine signaling does not remain limited to activated T cells. Their interactions with immune cells can reinforce inflammation and contribute to physiological changes associated with CRS, including effects on blood pressure, oxygenation, and organ function. Examining these cellular relationships provides a broader view of the syndrome’s biology.
Clinical grading organizes CRS severity according to the extent of systemic effects, such as fever, hypotension, hypoxia, and organ dysfunction. This creates a common framework for comparing patient responses, tracking progression, and evaluating management strategies. In cancer research, grading also helps relate clinical outcomes to biomarkers, cellular pathways, and treatment characteristics.
CRS biomarker studies examine measurable signals connected with immune-cell activation, cytokine production, and interactions involving endothelial and myeloid cells. Researchers can compare these signals with clinical findings and severity grades to evaluate whether they reflect disease progression or treatment response. Such analyses support efforts to improve patient monitoring and understand why inflammatory reactions differ among individuals.
A study typically links the immunotherapy exposure with clinical observation, measurement of relevant inflammatory signals, assessment of cellular pathways, and assignment of a clinical severity grade. Researchers then compare these findings with patient outcomes and responses to interventions. This integrated workflow connects molecular events with systemic manifestations rather than relying on a single laboratory or clinical measure.
Targeted interventions are evaluated by examining whether they modify the inflammatory pathways associated with CRS while preserving the intended cancer-immunotherapy response. Researchers can assess changes in clinical severity, cytokine-related biomarkers, cellular interactions, and organ effects. Comparing these outcomes helps determine whether an intervention provides useful control of inflammation and informs safer treatment strategies.
CRS research helps investigators balance immune activation against inflammatory toxicity. By connecting biomarkers, cellular mechanisms, clinical grading, and intervention responses, studies can identify ways to monitor patients more effectively and recognize concerning changes. These insights support the design of immunotherapies that retain therapeutic immune activity while improving safety and informing clinical management.